Subacute cutaneous lupus erythematosus (SCLE) is characterized by particular cutaneous manifestations such as non-scaring plaques mainly in sunlight exposed parts of the body along with specific serum autoantibodies (i.e. It is considered either idiopathic or drug induced. The role of chemotherapeutic agents in causing SCLE has been investigated with the taxanes being the most common anticancer agents. However, recent data emerging point toward antiestrogen therapies as a causative factor not only for SCLE but also for a variety of autoimmune disorders. This is a report of a case of a 42 year old woman who developed clinical manifestations of SCLE after letrozole treatment in whom remission of the cutaneous manifestations was noticed upon discontinuation of the drug. In addition, an extensive review of the English literature has been performed regarding the association of antiestrogen therapy with autoimmune disorders. In conclusion, Oncologists should be aware of the potential development of autoimmune reactions in breast cancer patients treated with aromatase inhibitors. Hussein Khaled is a Professor of Medical Oncology at the National Cancer Institute of Cairo University. The NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories. CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.
Tamoxifen (Nolvadex®) is a medication in pill form that has been used for more than 25 years to treat breast cancer in women and men. Tamoxifen is one of the most common endocrine therapy drugs. It has been shown to decrease the chance of recurrence in some early-stage breast cancers and to prevent the development of cancer in the opposite breast. Tamoxifen can also slow or stop the growth of cancer cells present in the body. There are an estimated 29 million women at increased risk for breast cancer in this country, and tamoxifen may offer another alternative to watchful waiting or prophylactic (preventative) mastectomy. Tamoxifen is classified as a selective estrogen receptor modulator (SERM) and works as an anti-estrogen: While the hormone estrogen promotes the growth of breast cancer cells, tamoxifen works by blocking estrogen from attaching to estrogen receptors on these cells. By blocking the estrogen receptors, it is believed that the growth of the breast cancer cells will be halted. Received date: January 01, 2011; Accepted date: February 27, 2011; Published date: March 08, 2011 Citation: Brahmi SA, Benjelloun H, Bouyahyaoui Y, Mernissi FZ, El Mesbahi O (2011) Delayed Maculopapular Eruption Induced by Tamoxifen. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. doi: 10.4172/1948-5956.1000063 Copyright: © 2011 Brahmi SA, et al. Visit for more related articles at Journal of Cancer Science & Therapy Tamoxifen has been the standard endocrine (anti-estrogen) therapy in breast cancer for several years. Few cutaneous adverse side-effects of the skin are found with this therapy. We report a case of a delayed tamoxifen-induced skin reaction. A 57-year-old, previously healthy, woman had a partial mastectomy in 2007 for a left-sided breast cancer. Histopathology revealed an invasive ductal carcinoma mesuring 2.5 cm. Both estrogen receptor and progesterone receptor were positive. Clinical examination revealed two cervical lymph nodes which the biopsy showed a ganglionnair tuberculosis.
Tamoxifen is used to treat certain types of breast cancer eg, estrogen. pinpoint red spots on the skin; pounding in the ears; skin rash or itching over the entire. Find information about tamoxifen, a medicine to treat breast cancer, from Cleveland. Hot flashes; Headache; Nausea and/or vomiting; Skin rash; Impotence.